Compare UGRO & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UGRO | VRAX |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United Kingdom |
| Employees | 130 | N/A |
| Industry | Industrial Specialties | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 1.7M |
| IPO Year | 2018 | 2021 |
| Metric | UGRO | VRAX |
|---|---|---|
| Price | $2.43 | $0.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 181.8K | ★ 187.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,008,850.00 | N/A |
| Revenue This Year | $98.41 | $217,274.83 |
| Revenue Next Year | $23.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.11 | $0.19 |
| 52 Week High | $4.50 | $1.58 |
| Indicator | UGRO | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 41.74 |
| Support Level | $0.28 | $0.20 |
| Resistance Level | $4.50 | $0.25 |
| Average True Range (ATR) | 0.30 | 0.02 |
| MACD | -0.12 | 0.00 |
| Stochastic Oscillator | 20.94 | 38.85 |
Urban-gro Inc operated as an integrated professional services and design-build firm offering architectural, engineering, and construction management solutions to the CEA, industrial, healthcare, and other commercial sectors. The company generated revenue by billing employees time on client projects and provided architectural, engineering, systems procurement and integration, and construction design-build solutions with a single point of accountability. For CEA clients, it developed indoor cultivation facilities for specialty crops, including cannabis and produce such as leafy greens, vegetables, herbs, and berries. Its segments included Equipment Systems (commercial horticulture equipment), Services (design-build services), and Construction Design-Build (general contracting).
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.